Invokana

OVERDOSE

There were no reports of overdose during the clinical
development program of INVOKANA (canagliflozin).

In the event of an overdose, contact the Poison Control
Center. It is also reasonable to employ the usual supportive measures, e.g.,
remove unabsorbed material from the gastrointestinal tract, employ clinical
monitoring, and institute supportive treatment as dictated by the patient's
clinical status. Canagliflozin was negligibly removed during a 4-hour
hemodialysis session. Canagliflozin is not expected to be dialyzable by
peritoneal dialysis.

CONTRAINDICATIONS

History of a serious hypersensitivity reaction to
INVOKANA [see WARNINGS AND PRECAUTIONS].